RLAY
Relay Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+43/100
Last price
18.87
▼ 0.52 (2.68%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
19.22
Prev close
19.39
Day high
19.50
Day low
18.17
Volume
3.88M
Market cap
$4.11B
P/E (TTM)
—
52W range
5.83 – 21.27
Day trading desk
Gap from prior close
-0.88%
Prior close 19.39
VWAP
18.50
+1.98% from price
Relative volume
2.30×
Unusually busy
Session range
7.32%
18.17 – 19.50
Position in range
53%
Mid range
ATR (14D)
1.02
5.40% of price
Prior day high
19.40
PDH
Prior day low
18.28
PDL
Bid / ask spread
—
Quote not published
Session volume
6.42M
Avg 2.80M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.07%
+0.1%
1M
-1.58%
-2.7%
3M
-4.53%
-9.1%
6M
+39.02%
+20.8%
YTD
+121.51%
+107.3%
1Y
+241.97%
+225.6%
3Y
+122.83%
+40.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RLAY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-6.32M
Net selling
Buy transactions
5
270.81K shares
Sell transactions
21
6.59M shares
Net transactions
+26
Buys less sells
Sell : buy shares
24.4 : 1
Heavily one-sided
Insider-held shares
3.52M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 8, 26 | BERGSTROM DONALD A. Officer |
SELL | 8.53K | $161.81K | Direct |
| Sep 8, 26 | PATEL SANJIV NARATANBHAI Chief Executive Officer |
SELL | 48.20K | $912.89K | Direct |
| Sep 8, 26 | CATINAZZO THOMAS J Chief Financial Officer |
SELL | 17.72K | $335.56K | Direct |
| Aug 26, 26 | RAHMER PETER J Officer |
SELL | 4.51K | $90.30K | Direct |
| Aug 25, 26 | SVF PAULING CAYMAN LTD Beneficial Owner of more than 10% of a Class of Security |
SELL | 6.00M | $116.40M | Indirect |
| Aug 17, 26 | PATEL SANJIV NARATANBHAI Chief Executive Officer |
SELL | 48.20K | $979.89K | Direct |
| Aug 14, 26 | CATINAZZO THOMAS J Chief Financial Officer |
SELL | 17.72K | $349.73K | Direct |
| Jul 28, 26 | BERGSTROM DONALD A. Officer |
SELL | 2.24K | $41.63K | Direct |
| Jul 28, 26 | CATINAZZO THOMAS J Chief Financial Officer |
SELL | 1.46K | $27.15K | Direct |
| Jul 28, 26 | RAHMER PETER J Officer |
SELL | 748 | $13.92K | Direct |
| Jul 7, 26 | PATEL SANJIV NARATANBHAI Chief Executive Officer |
SELL | 48.20K | $943.74K | Direct |
| Jul 6, 26 | BERGSTROM DONALD A. Officer |
SELL | 8.66K | $162.03K | Direct |
| Jul 6, 26 | CATINAZZO THOMAS J Chief Financial Officer |
SELL | 17.72K | $331.13K | Direct |
| Jun 30, 26 | PATEL SANJIV NARATANBHAI Chief Executive Officer |
STOCK | 3.06K | $57.18K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAMS BRIAN R |
Officer | 371.47K | Sale |
BERGSTROM DONALD A. |
Officer | 399.13K | Sale |
CATINAZZO THOMAS J |
Chief Financial Officer | 122.85K | Sale |
PATEL SANJIV NARATANBHAI |
Chief Executive Officer | 1.41M | Sale |
RAHMER PETER J |
Officer | 223.66K | Sale |
SVF PAULING CAYMAN LTD |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Fundamentals
Market cap$4.11B
Enterprise value$3.23B
Revenue (TTM)$10.35M
Gross profit$-258.50M
EBITDA$-308.22M
Net income$-286.04M
EPS (TTM)$-1.51
Free cash flow$-119.24M
Total cash$910.93M
Total debt$30.66M
Book value / share$4.07
Shares outstanding219.14M
Float145.48M
Short % of float23.64%
Dividend yield0.00%
Beta (5Y)1.73
Valuation & profitability ratios
Trailing P/E—
Forward P/E-11.48
PEG ratio—
Price / sales—
Price / book4.60
EV / revenue311.73
EV / EBITDA-10.47
Gross margin0.00%
Operating margin-25949.72%
Profit margin0.00%
Return on equity-36.77%
Return on assets-22.88%
Debt / equity3.45
Current ratio18.27
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $15.36M | $10.01M | $25.55M | $1.38M | +53.4% |
| Operating revenue | $15.36M | $10.01M | $25.55M | $1.38M | +53.4% |
| Research & development | $261.38M | $319.09M | $330.02M | $246.35M | -18.1% |
| Selling, general & admin | $56.71M | $76.59M | $74.95M | $65.98M | -26.0% |
| Total operating expense | $318.09M | $395.68M | $404.97M | $312.33M | -19.6% |
| Operating income | -$302.74M | -$385.67M | -$379.42M | -$310.95M | +21.5% |
| Net interest income | $27.04M | $34.75M | $31.05M | $8.79M | -22.2% |
| Pre-tax income | -$276.48M | -$337.71M | -$341.97M | -$290.51M | +18.1% |
| Net income | -$276.48M | -$337.71M | -$341.97M | -$290.51M | +18.1% |
| Net income to common | -$276.48M | -$337.71M | -$341.97M | -$290.51M | +18.1% |
| Basic EPS | -1.61 | -2.36 | -2.79 | -2.59 | +31.8% |
| Diluted EPS | -1.61 | -2.36 | -2.79 | -2.59 | +31.8% |
| EBIT | -$302.74M | -$385.67M | -$379.42M | -$310.95M | +21.5% |
| EBITDA | -$299.18M | -$380.21M | -$374.15M | -$306.82M | +21.3% |
| Basic shares | 171.59M | 142.87M | 122.58M | 112.23M | +20.1% |
| Diluted shares | 171.59M | 142.87M | 122.58M | 112.23M | +20.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $84.02M | $124.29M | $143.74M | $151.79M | — | -32.4% |
| Cash & short-term investments | $554.52M | $781.32M | $750.09M | $998.92M | — | -29.0% |
| Accounts receivable | — | — | $0 | $306.00K | $403.00K | — |
| Total current assets | $578.28M | $809.20M | $770.10M | $1.02B | — | -28.5% |
| Property, plant & equipment | $41.72M | $57.67M | $68.87M | $75.39M | — | -27.7% |
| Goodwill & intangibles | $0 | $2.30M | $2.30M | $2.30M | — | -100.0% |
| Total assets | $621.33M | $871.30M | $843.98M | $1.10B | — | -28.7% |
| Total current liabilities | $25.58M | $50.73M | $30.27M | $63.71M | — | -49.6% |
| Total debt | $32.46M | $48.50M | $53.47M | $57.74M | — | -33.1% |
| Total liabilities | $54.27M | $93.50M | $91.98M | $149.55M | — | -42.0% |
| Retained earnings | -$2.01B | -$1.74B | -$1.40B | -$1.06B | — | -15.9% |
| Shareholder equity | $567.06M | $777.79M | $752.00M | $950.22M | — | -27.1% |
| Working capital | $552.70M | $758.48M | $739.83M | $955.80M | — | -27.1% |
| Net tangible assets | $567.06M | $775.49M | $749.70M | $947.92M | — | -26.9% |
| Shares issued | 173.87M | 167.76M | 127.46M | 121.11M | — | +3.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$276.48M | -$337.71M | -$341.97M | -$290.51M | +18.1% |
| Depreciation & amortisation | $3.56M | $5.46M | $5.27M | $4.13M | -34.9% |
| Stock-based compensation | $62.42M | $94.14M | $86.03M | $56.14M | -33.7% |
| Change in working capital | -$23.31M | $14.62M | -$32.46M | $11.25M | -259.4% |
| Operating cash flow | -$235.46M | -$249.11M | -$300.32M | -$229.49M | +5.5% |
| Capital expenditure | -$410.00K | -$2.02M | -$4.13M | -$9.06M | +79.7% |
| Investing cash flow | $192.80M | -$41.08M | $257.63M | -$188.75M | +569.3% |
| Financing cash flow | $1.60M | $270.15M | $34.75M | $289.91M | -99.4% |
| Free cash flow | -$235.87M | -$251.13M | -$304.44M | -$238.55M | +6.1% |
| End cash position | $85.35M | $126.41M | $146.44M | $154.37M | -32.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $350.00K | $3.00M | $7.00M | $0 | $677.00K | -88.3% |
| Operating revenue | $350.00K | $3.00M | $7.00M | $0 | $677.00K | -88.3% |
| Research & development | $76.48M | $70.56M | $55.41M | $68.26M | $63.90M | +8.4% |
| Selling, general & admin | $14.69M | $11.03M | $12.21M | $12.13M | $13.63M | +33.2% |
| Total operating expense | $91.17M | $81.59M | $67.63M | $80.39M | $77.52M | +11.7% |
| Operating income | -$90.82M | -$78.59M | -$60.63M | -$80.39M | -$76.85M | -15.6% |
| Net interest income | $7.12M | $5.35M | $5.71M | $6.41M | $7.11M | +32.9% |
| Pre-tax income | -$83.71M | -$73.29M | -$54.89M | -$74.15M | -$70.38M | -14.2% |
| Net income | -$83.71M | -$73.29M | -$54.89M | -$74.15M | -$70.38M | -14.2% |
| Net income to common | -$83.71M | -$73.29M | -$54.89M | -$74.15M | -$70.38M | -14.2% |
| Basic EPS | -0.41 | -0.41 | -0.32 | -0.43 | -0.41 | 0.0% |
| Diluted EPS | -0.41 | -0.41 | -0.32 | -0.43 | -0.41 | 0.0% |
| EBIT | -$90.82M | -$78.59M | -$60.63M | -$80.39M | -$76.85M | -15.6% |
| EBITDA | -$90.46M | -$78.09M | -$60.03M | -$79.64M | -$75.84M | -15.9% |
| Basic shares | 202.85M | 179.85M | 173.40M | 172.39M | 171.26M | +12.8% |
| Diluted shares | 202.85M | 179.85M | 173.40M | 172.39M | 171.26M | +12.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $121.19M | $204.59M | $84.02M | $91.56M | $113.94M | — | -40.8% |
| Cash & short-term investments | $910.93M | $642.07M | $554.52M | $596.43M | $656.77M | — | +41.9% |
| Total current assets | $928.08M | $658.46M | $578.28M | $624.01M | $680.39M | — | +40.9% |
| Property, plant & equipment | $38.04M | $39.81M | $41.72M | $43.73M | $46.19M | — | -4.5% |
| Goodwill & intangibles | — | — | $0 | $0 | $0 | $2.30M | — |
| Total assets | $967.46M | $699.61M | $621.33M | $670.00M | $728.84M | — | +38.3% |
| Total current liabilities | $50.80M | $29.75M | $25.58M | $32.60M | $32.52M | — | +70.8% |
| Total debt | $30.66M | $31.57M | $32.46M | $33.33M | $34.18M | — | -2.9% |
| Total liabilities | $77.45M | $57.43M | $54.27M | $62.29M | $63.18M | — | +34.9% |
| Retained earnings | -$2.17B | -$2.09B | -$2.01B | -$1.96B | -$1.89B | — | -4.0% |
| Shareholder equity | $890.01M | $642.18M | $567.06M | $607.71M | $665.66M | — | +38.6% |
| Working capital | $877.28M | $628.71M | $552.70M | $591.41M | $647.87M | — | +39.5% |
| Net tangible assets | $890.01M | $642.18M | $567.06M | $607.71M | $665.66M | — | +38.6% |
| Shares issued | 218.53M | 189.21M | 173.87M | 172.63M | 171.69M | — | +15.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$83.71M | -$73.29M | -$54.89M | -$74.15M | -$70.38M | — | -14.2% |
| Depreciation & amortisation | $360.00K | $504.00K | $599.00K | $748.00K | $1.00M | — | -28.6% |
| Stock-based compensation | $9.18M | $10.54M | $13.07M | $15.53M | $14.50M | — | -12.9% |
| Change in working capital | $20.68M | $11.92M | -$2.82M | -$3.50M | -$1.91M | — | +73.5% |
| Operating cash flow | -$54.11M | -$51.11M | -$44.87M | -$62.12M | -$55.26M | — | -5.9% |
| Capital expenditure | — | — | -$1.00K | — | -$26.00K | -$384.00K | — |
| Investing cash flow | -$353.03M | $32.90M | $35.46M | $39.73M | $75.15M | — | -1,173.0% |
| Financing cash flow | $323.74M | $138.78M | $934.00K | $17.00K | $653.00K | — | +133.3% |
| Free cash flow | -$54.11M | -$51.11M | -$44.87M | -$62.12M | -$55.29M | — | -5.9% |
| End cash position | $122.53M | $205.93M | $85.35M | $93.82M | $116.20M | — | -40.5% |
Options analytics
Put / call volume
5.13
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
14.00
-25.3% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
40
Contracts, this expiry
Put volume
205
Contracts, this expiry
Heaviest call OI
17.00
0 contracts
Heaviest put OI
14.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.39 | -0.41 | -4.4% |
| Mar 2026 | -0.36 | -0.41 | -15.0% |
| Dec 2025 | -0.40 | -0.31 | +21.7% |
| Sep 2025 | -0.42 | -0.43 | -2.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.40 | 11 | $1.58M | 0.0% |
| Next quarter | -0.38 | 11 | $7.77M | +11.0% |
| Current year | -1.61 | 11 | $11.16M | -27.3% |
| Next year | -1.63 | 11 | $17.94M | +60.7% |
Analyst targets & ownership
Mean target$27.58
High target$32.00
Low target$20.00
Implied upside46.18%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy3 / 10
Hold0
Sell / Strong sell0 / 0
Held by insiders1.61%
Held by institutions110.84%
Institutions holding350
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.29
+3.17% from price
SMA 20
18.59
+0.82% from price
SMA 50
19.11
-1.96% from price
SMA 100
17.80
+6.00% from price
SMA 200
14.12
+32.75% from price
EMA 12
18.60
+1.46% from price
EMA 26
18.70
+0.89% from price
EMA 50
18.63
+1.31% from price
RSI (14)
50.3
Neutral
MACD (12,26,9)
-0.10
Hist 0.10
ATR (14)
1.02
5.44% of price
Realised vol 30D
44.7%
Annualised
Bollinger upper
19.69
20, 2σ
Bollinger lower
17.49
20, 2σ
50 / 200 cross
Golden
19.11 vs 14.12
Trend bias
Above 200
+32.75%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.42
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
44.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.2%
Peak to trough
Max drawdown 5Y
-94.6%
Peak to trough
ATR 14
1.02
5.44% of price
Beta (reported)
1.73
5Y monthly, from filing
Short interest
Shares short
44.49M
Prior 41.36M
Change vs prior
+7.6%
Shorts adding
% of float
23.64%
Heavily shorted
% of shares out
20.30%
Against total outstanding
Days to cover
15.3
Crowded exit
Float
145.48M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 14, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 10, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 7, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 21, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Jul 16, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Jul 8, 26 | JP Morgan | INITIATED | — | Overweight |
| May 26, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| May 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 20, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| May 20, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| May 19, 26 | Raymond James | MAINTAINED | Strong Buy | Strong Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-05-05
Proxy Statements
DEF 14A · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-04-27
Proxy Statements
PRE 14A · 2026-04-16
Corporate Changes & Voting Matters
8-K · 2026-03-16
Corporate Changes & Voting Matters
8-K · 2026-03-11
Headlines
Raymond James Updates Healthcare Top Picks for October
Investing.com · 5d ago
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Zacks · 13d ago
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
GlobeNewswire · 15d ago
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing
MT Newswires · 27d ago
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Zacks · 34d ago
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Motley Fool · 34d ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
GlobeNewswire · 35d ago
This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion
Investor's Business Daily · 46d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.